{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:48:47Z","timestamp":1787021327493,"version":"build-2736575974"},"reference-count":78,"publisher":"The Company of Biologists","issue":"5","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Fabry nephropathy is a major cause of kidney failure in Fabry disease, caused by pathogenic GLA variants that reduce \u03b1-galactosidase A activity and lead to globotriaosylceramide (Gb3) accumulation. In recent years, rapid advances in experimental modeling and emerging therapeutic strategies have dramatically reshaped understanding and treatment prospects for Fabry nephropathy. Experimental models \u2013 including cellular systems, patient-derived kidney organoids, and animal models such as zebrafish, Drosophila, mice and rats \u2013 have been pivotal in elucidating classic Gb3-dependent and novel Gb3-independent pathogenic mechanisms. These insights challenge the traditional Gb3-centric paradigm by highlighting other contributors, such as its metabolite lyso-Gb3, as well as \u03b1-synuclein accumulation and endothelial dysfunction. Despite established therapies for Fabry nephropathy, such as enzyme replacement and pharmacological chaperones, disease progression remains a clinical challenge, underscoring the urgent need for deeper mechanistic understanding and precision medicine approaches. This timely Review summarizes diverse model systems' unique strengths, limitations and translational potential to guide future research and therapeutic development for this complex disease.<\/jats:p>","DOI":"10.1242\/dmm.052716","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:12:53Z","timestamp":1780045973000},"source":"Crossref","is-referenced-by-count":2,"title":["Modeling Fabry nephropathy: insights from experimental systems towards precision nephrology"],"prefix":"10.1242","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-0245","authenticated-orcid":false,"given":"Hassan","family":"Elsaid","sequence":"first","affiliation":[{"name":"University of Bergen 1 Department of Clinical Medicine , , 5020 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Furriol","sequence":"additional","affiliation":[{"name":"University of Bergen 1 Department of Clinical Medicine , , 5020 Bergen ,","place":["Norway"]},{"name":"Haukeland University Hospital 2 Department of Medicine , , 5021 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Eikrem","sequence":"additional","affiliation":[{"name":"University of Bergen 1 Department of Clinical Medicine , , 5020 Bergen ,","place":["Norway"]},{"name":"Haukeland University Hospital 2 Department of Medicine , , 5021 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[{"name":"University of Bergen 1 Department of Clinical Medicine , , 5020 Bergen ,","place":["Norway"]},{"name":"Haukeland University Hospital 3 Department of Pediatrics , , 5021 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[{"name":"University of Bergen 1 Department of Clinical Medicine , , 5020 Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026052905124921400_DMM052716C1","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026052905124921400_DMM052716C2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12951-022-01318-8","article-title":"Ceria-Zirconia nanoparticles reduce intracellular globotriaosylceramide accumulation and attenuate kidney injury by enhancing the autophagy flux in cellular and animal models of Fabry disease","volume":"20","author":"An","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"2026052905124921400_DMM052716C3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","article-title":"Lysosomes as dynamic regulators of cell and organismal homeostasis","volume":"21","author":"Ballabio","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026052905124921400_DMM052716C4","doi-asserted-by":"publisher","first-page":"e157782","DOI":"10.1172\/JCI157782","article-title":"Accumulation of alpha-synuclein mediates podocyte injury in Fabry nephropathy","volume":"133","author":"Braun","year":"2023","journal-title":"J. Clin. Invest."},{"key":"2026052905124921400_DMM052716C5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.33594\/000000077","article-title":"Enzyme replacement therapy clears Gb3 deposits from a podocyte cell culture model of Fabry disease but fails to restore altered cellular signaling","volume":"52","author":"Braun","year":"2019","journal-title":"Cell. Physiol. Biochem."},{"key":"2026052905124921400_DMM052716C6","doi-asserted-by":"publisher","first-page":"7397","DOI":"10.3390\/ijms21197397","article-title":"Misfolding of lysosomal alpha-galactosidase a in a fly model and its alleviation by the pharmacological chaperone Migalastat","volume":"21","author":"Braunstein","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2026052905124921400_DMM052716C7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1681\/ASN.2006080822","article-title":"Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice","volume":"18","author":"Christensen","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"2026052905124921400_DMM052716C8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.23876\/j.krcp.20.264","article-title":"Fabry disease exacerbates renal interstitial fibrosis after unilateral ureteral obstruction via impaired autophagy and enhanced apoptosis","volume":"40","author":"Chung","year":"2021","journal-title":"Kidney Res. Clin. Pract."},{"key":"2026052905124921400_DMM052716C9","doi-asserted-by":"publisher","first-page":"100926","DOI":"10.1016\/j.ymgmr.2022.100926","article-title":"\u03b1-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response","volume":"33","author":"Consolato","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"2026052905124921400_DMM052716C10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12967-023-03992-0","article-title":"Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system","volume":"21","author":"Cui","year":"2023","journal-title":"J. Transl. Med."},{"key":"2026052905124921400_DMM052716C11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.trsl.2023.02.005","article-title":"CRISPR\/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model","volume":"258","author":"Cui","year":"2023","journal-title":"Transl. Res."},{"key":"2026052905124921400_DMM052716C12","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.ymgmr.2022.100851","article-title":"Reduced alpha-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype","volume":"31","author":"Elsaid","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"2026052905124921400_DMM052716C13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s12967-023-04475-y","article-title":"Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla\u2212\/\u2212 zebrafish model of Fabry disease","volume":"21","author":"Elsaid","year":"2023","journal-title":"J. Transl. Med."},{"key":"2026052905124921400_DMM052716C14","doi-asserted-by":"publisher","first-page":"e0168346","DOI":"10.1371\/journal.pone.0168346","article-title":"Urinary podocyte loss is increased in patients with fabry disease and correlates with clinical severity of fabry nephropathy","volume":"11","author":"Fall","year":"2016","journal-title":"PLoS ONE"},{"key":"2026052905124921400_DMM052716C15","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J."},{"key":"2026052905124921400_DMM052716C16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1159\/000544760","article-title":"The inflammatory pathogenetic pathways of fabry nephropathy and agalopathy: GLA variant induction of endoplasmic reticulum stress","volume":"149","author":"Feriozzi","year":"2025","journal-title":"Nephron"},{"key":"2026052905124921400_DMM052716C17","doi-asserted-by":"publisher","first-page":"8715","DOI":"10.1038\/ncomms9715","article-title":"Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids","volume":"6","author":"Freedman","year":"2015","journal-title":"Nat. Commun."},{"key":"2026052905124921400_DMM052716C18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41563-019-0287-6","article-title":"Fine tuning the extracellular environment accelerates the derivation of kidney organoids from human pluripotent stem cells","volume":"18","author":"Garreta","year":"2019","journal-title":"Nat. Mater."},{"key":"2026052905124921400_DMM052716C19","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S0248-8663(00)00269-1","article-title":"[Fabry disease. Clinical and genetic aspects. Therapeutic perspectives]","volume":"21","author":"Germain","year":"2000","journal-title":"Rev. Med. Interne"},{"key":"2026052905124921400_DMM052716C20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"2026052905124921400_DMM052716C21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"2026052905124921400_DMM052716C22","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet. Med."},{"key":"2026052905124921400_DMM052716C23","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1186\/1755-1536-5-S1-S15","article-title":"Progression of renal fibrosis: the underestimated role of endothelial alterations","volume":"5","author":"Guerrot","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2026052905124921400_DMM052716C24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/bios13030339","article-title":"Co-culture of glomerular endothelial cells and podocytes in a custom-designed glomerulus-on-a-chip model improves the filtration barrier integrity and affects the glomerular cell phenotype","volume":"13","author":"Hart","year":"2023","journal-title":"Biosensors (Basel)"},{"key":"2026052905124921400_DMM052716C25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fped.2017.00262","article-title":"Using the Drosophila nephrocyte to model podocyte function and disease","volume":"5","author":"Helmstadter","year":"2017","journal-title":"Front. Pediatr."},{"key":"2026052905124921400_DMM052716C26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41592-019-0325-y","article-title":"Flow-enhanced vascularization and maturation of kidney organoids in vitro","volume":"16","author":"Homan","year":"2019","journal-title":"Nat. Methods"},{"key":"2026052905124921400_DMM052716C27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2183\/pjab.88.18","article-title":"Pharmacological chaperone therapy for Fabry disease","volume":"88","author":"Ishii","year":"2012","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"2026052905124921400_DMM052716C28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","article-title":"Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease","volume":"1690","author":"Ishii","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"2026052905124921400_DMM052716C29","doi-asserted-by":"publisher","first-page":"11339","DOI":"10.3390\/ijms222111339","article-title":"\u03b1-galactosidase a deficiency in fabry disease leads to extensive dysregulated cellular signaling pathways in human podocytes","volume":"22","author":"Jehn","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2026052905124921400_DMM052716C30","doi-asserted-by":"publisher","first-page":"e0136442","DOI":"10.1371\/journal.pone.0136442","article-title":"Epithelial-mesenchymal transition in kidney tubular epithelial cells induced by globotriaosylsphingosine and globotriaosylceramide","volume":"10","author":"Jeon","year":"2015","journal-title":"PLoS ONE"},{"key":"2026052905124921400_DMM052716C31","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1073\/pnas.051634498","article-title":"Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice","volume":"98","author":"Jung","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026052905124921400_DMM052716C32","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"2026052905124921400_DMM052716C33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol. Ther."},{"key":"2026052905124921400_DMM052716C34","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","article-title":"Human kidney organoids reveal the role of glutathione in Fabry disease","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"2026052905124921400_DMM052716C35","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1021\/acsanm.3c05170","article-title":"PEG-capped ceria\u2013zirconia nanoparticles improved renal fibrosis in cellular and animal models of fabry disease","volume":"7","author":"Kim","year":"2024","journal-title":"ACS Appl. Nano Mater."},{"key":"2026052905124921400_DMM052716C36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.11477\/mf.1416202749","article-title":"[Pharmacological chaperone therapy for Fabry disease]","volume":"76","author":"Kobayashi","year":"2024","journal-title":"Brain Nerve"},{"key":"2026052905124921400_DMM052716C37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/biom11020271","article-title":"Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions","volume":"11","author":"Kok","year":"2021","journal-title":"Biomolecules"},{"key":"2026052905124921400_DMM052716C38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ymgme.2013.10.010","article-title":"Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease","volume":"111","author":"Labilloy","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"2026052905124921400_DMM052716C39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41563-020-00853-9","article-title":"Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation","volume":"20","author":"Lawlor","year":"2021","journal-title":"Nat. Mater."},{"key":"2026052905124921400_DMM052716C40","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","article-title":"Possible role of transforming growth factor-\u03b21 and vascular endothelial growth factor in Fabry disease nephropathy","volume":"30","author":"Lee","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"2026052905124921400_DMM052716C41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: the current treatment landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"2026052905124921400_DMM052716C42","doi-asserted-by":"publisher","first-page":"e63506","DOI":"10.1371\/journal.pone.0063506","article-title":"Dysregulated autophagy contributes to podocyte damage in Fabry's disease","volume":"8","author":"Liebau","year":"2013","journal-title":"PLoS ONE"},{"key":"2026052905124921400_DMM052716C43","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1101\/gad.329573.119","article-title":"Kidney organoids: accurate models or fortunate accidents","volume":"33","author":"Little","year":"2019","journal-title":"Genes Dev."},{"key":"2026052905124921400_DMM052716C44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.stem.2019.06.009","article-title":"Generation of human PSC-derived kidney organoids with patterned nephron segments and a De Novo vascular network","volume":"25","author":"Low","year":"2019","journal-title":"Cell Stem Cell"},{"key":"2026052905124921400_DMM052716C45","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3390\/ijms21030956","article-title":"Assessment of gene variant amenability for pharmacological chaperone therapy with 1-deoxygalactonojirimycin in fabry disease","volume":"21","author":"Lukas","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2026052905124921400_DMM052716C46","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1096\/fj.201701374R","article-title":"Medullary thick ascending limb impairment in the Gla tm Tg(CAG-A4GALT) Fabry model mice","volume":"32","author":"Maruyama","year":"2018","journal-title":"FASEB J."},{"key":"2026052905124921400_DMM052716C47","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1096\/fj.201800771R","article-title":"\u03b1-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease","volume":"33","author":"Miller","year":"2018","journal-title":"FASEB J."},{"key":"2026052905124921400_DMM052716C48","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nbt.3392","article-title":"Nephron organoids derived from human pluripotent stem cells model kidney development and injury","volume":"33","author":"Morizane","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"2026052905124921400_DMM052716C49","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"2026052905124921400_DMM052716C50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of Globotriaosylceramide in podocytes in fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"2026052905124921400_DMM052716C51","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-galactosidase a deficient mice: a model of fabrydisease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026052905124921400_DMM052716C52","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"2026052905124921400_DMM052716C53","doi-asserted-by":"publisher","first-page":"F1015","DOI":"10.1152\/ajprenal.00283.2016","article-title":"Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR\/Cas9 technology","volume":"311","author":"Pereira","year":"2016","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"2026052905124921400_DMM052716C54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm2199","article-title":"Signal integration in the endoplasmic reticulum unfolded protein response","volume":"8","author":"Ron","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026052905124921400_DMM052716C55","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2019.10.010","article-title":"Pathogenesis of Fabry nephropathy: the pathways leading to fibrosis","volume":"129","author":"Rozenfeld","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"2026052905124921400_DMM052716C56","doi-asserted-by":"publisher","first-page":"1386042","DOI":"10.3389\/fcvm.2024.1386042","article-title":"The role of tubular cells in the pathogenesis of Fabry nephropathy","volume":"11","author":"Rozenfeld","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"2026052905124921400_DMM052716C57","doi-asserted-by":"publisher","first-page":"100494","DOI":"10.1016\/j.ymgmr.2019.100494","article-title":"The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease","volume":"20","author":"Schiffmann","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"2026052905124921400_DMM052716C58","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/jimd.12373","article-title":"Defective lysosomal storage in Fabry disease modifies mitochondrial structure, metabolism and turnover in renal epithelial cells","volume":"44","author":"Schumann","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"2026052905124921400_DMM052716C59","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1093\/ndt\/gfr084","article-title":"Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique","volume":"26","author":"Selvarajah","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"2026052905124921400_DMM052716C60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jb\/mvq125","article-title":"Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease","volume":"149","author":"Shiozuka","year":"2011","journal-title":"J. Biochem."},{"key":"2026052905124921400_DMM052716C61","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1002\/dvdy.21569","article-title":"Discovery and characterization of three novel synuclein genes in zebrafish","volume":"237","author":"Sun","year":"2008","journal-title":"Dev. Dyn."},{"key":"2026052905124921400_DMM052716C62","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1042\/BJ20130825","article-title":"A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis","volume":"456","author":"Taguchi","year":"2013","journal-title":"Biochem. J."},{"key":"2026052905124921400_DMM052716C63","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature15695","article-title":"Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis","volume":"526","author":"Takasato","year":"2015","journal-title":"Nature"},{"key":"2026052905124921400_DMM052716C64","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/ki.2008.576","article-title":"Downregulation of \u03b1-galactosidase A upregulates CD77: functional impact for Fabry nephropathy","volume":"75","author":"Thomaidis","year":"2009","journal-title":"Kidney Int."},{"key":"2026052905124921400_DMM052716C65","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"2026052905124921400_DMM052716C66","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"Tondel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"2026052905124921400_DMM052716C67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"Tondel","year":"2015","journal-title":"Nephron"},{"key":"2026052905124921400_DMM052716C68","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymgme.2022.10.005","article-title":"Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues","volume":"137","author":"Tondel","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"2026052905124921400_DMM052716C69","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.devcel.2019.06.001","article-title":"In vivo developmental trajectories of human podocyte inform in vitro differentiation of pluripotent stem cell-derived podocytes","volume":"50","author":"Tran","year":"2019","journal-title":"Dev. Cell"},{"key":"2026052905124921400_DMM052716C70","doi-asserted-by":"publisher","first-page":"10088","DOI":"10.3390\/ijms221810088","article-title":"Pathogenesis and molecular mechanisms of anderson-fabry disease and possible new molecular addressed therapeutic strategies","volume":"22","author":"Tuttolomondo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2026052905124921400_DMM052716C71","doi-asserted-by":"publisher","first-page":"837828","DOI":"10.3389\/fcell.2022.837828","article-title":"Using Drosophila nephrocytes to understand the formation and maintenance of the podocyte slit diaphragm","volume":"10","author":"van de Leemput","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"2026052905124921400_DMM052716C72","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.stemcr.2018.01.041","article-title":"Renal subcapsular transplantation of PSC-derived kidney organoids induces neo-vasculogenesis and significant glomerular and tubular maturation in vivo","volume":"10","author":"van den Berg","year":"2018","journal-title":"Stem Cell Rep."},{"key":"2026052905124921400_DMM052716C73","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","volume":"43","author":"van der Veen","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"2026052905124921400_DMM052716C74","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.ackd.2006.01.013","article-title":"Diagnosis and management of kidney involvement in Fabry disease","volume":"13","author":"Warnock","year":"2006","journal-title":"Adv. Chronic Kidney Dis."},{"key":"2026052905124921400_DMM052716C75","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2215\/CJN.06900909","article-title":"Enzyme replacement therapy and Fabry nephropathy","volume":"5","author":"Warnock","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2026052905124921400_DMM052716C76","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/nature07526","article-title":"The insect nephrocyte is a podocyte-like cell with a filtration slit diaphragm","volume":"457","author":"Weavers","year":"2009","journal-title":"Nature"},{"key":"2026052905124921400_DMM052716C77","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.stem.2018.10.010","article-title":"Comparative analysis and refinement of human PSC-derived kidney organoid differentiation with single-cell transcriptomics","volume":"23","author":"Wu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2026052905124921400_DMM052716C78","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1681\/ASN.0000000535","article-title":"Misprocessing of alpha -Galactosidase A, Endoplasmic Reticulum Stress, and the Unfolded Protein Response","volume":"36","author":"Zivna","year":"2025","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.052716\/3701413\/dmm052716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.052716\/3701413\/dmm052716.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:12:54Z","timestamp":1780045974000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/19\/5\/dmm052716\/371846\/Modeling-Fabry-nephropathy-insights-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.052716","relation":{},"ISSN":["1754-8403","1754-8411"],"issn-type":[{"value":"1754-8403","type":"print"},{"value":"1754-8411","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"dmm052716"}}